

Outcome measures for ALS clinical trials

Traynor et al. studied the predictive value of outcome measures in 97 placebo-treated ALS patients enrolled in a randomized clinical trial. FVC% and ALSFRS (but not MVIC arm or grip) declined linearly over a 12-month period and were prognostic for survival.


see page 1933

Finding a treatment for ALS: A practical, meaningful clinical endpoint

Commentary by Robert C. Griggs, MD

From January 1997 to January 2005, *Neurology* will have published over 150 articles on ALS. In addition, we have had 10 editorials or commentaries. Many have considered treatment. None has reported a home run¹ but four have reported supportive treatments and one a treatable ALS look-alike.² Many have considered clinical trial outcomes. There are now many new treatment strategies that deserve study in clinical trials. Survival was the outcome in the successful trials of riluzole in ALS. However, as Traynor et al. note, it is a costly endpoint requiring long follow-up of a large number of patients. Manual or machine motor testing quantitate the effect of motor neuron loss on strength and have an irresistible, intuitive appeal. However, they are costly and have either not performed well or not been used in most trials.

As an important by-product of the North East ALS (NEALS) Consortium failed topiramate trial,³ Traynor et al. report that two low-cost, easily performed tests of motor function—forced vital capacity (FVC) and ALS Functional Rating Score (ALSFRS)—decline linearly and predict survival. Machine-based mechanical motor testing did neither.



Survival of placebo-treated ALS patients according to their rate of decline of FVC%.

Should these measures be adopted in new ALS trials? They clearly stack up well vs survival and expensive labor-intensive tests that cannot be used by everyone in all sites.

Complete proof of concept will require their successful use in an effective treatment but their assessment even in other negative trials should confirm their potential value.⁴

References

1. Kaufmann P, Lomen-Hoerth C. ALS treatment strikes out while trying for

a homer: the topiramate trial. *Neurology* 2003;61:434–435.

2. Jubelt B, Berger JR. Does viral disease underlie ALS? Lessons from the AIDS pandemic. *Neurology* 2001;57:945–946.
3. Cudkovic ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. *Neurology* 2003;61:456–464.
4. Kaufmann P, Levy G, Thompson JLP, et al. The ALSFRS_r predicts survival time in ALS clinical population. *Neurology* 2005 (in press).

see page 1933

Neurology[®]

November 23 Highlight and Commentary

Neurology 2004;63;1765
DOI 10.1212/WNL.63.10.1765

This information is current as of November 22, 2004

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/63/10/1765.full
References	This article cites 3 articles, 3 of which you can access for free at: http://n.neurology.org/content/63/10/1765.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/63/10/1765.full##otherarticles
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

